Maze Therapeutics Q3 results miss estimates on higher R&D spending
MAZE•Maze Therapeutics reported a Q3 net loss of $47.97 million, missing the $46.11 million analyst estimate, and an operating loss of $51.52 million, also below expectations. It ended the quarter with $477 million in cash and expects key Phase 2 data in 2027.
1. Q3 results
Maze Therapeutics’ Q3 net loss was $47.97 million, compared with an analyst estimate of $46.11 million. Its operating loss was $51.52 million, versus an estimated $48.98 million. The company said higher research and development expenses reflected progress in its MZE829 and MZE782 clinical programs and increased personnel costs; general and administrative expenses also rose due to personnel costs and professional services.
2. Cash and trials
Maze ended Q3 with $477 million in cash, which it said supports its runway into 2029. The company expects HORIZON Phase 2 trial data for MZE829 in early 2027 and topline data from the MZE782 Phase 2 CIPheR trial in PKU in 2027. It plans to initiate a Phase 2 CKD trial for MZE782 in the first half of 2027.
